Johnson & Johnson closes Firefly buy for $1B, inks Sail deal; 2026 EPS guidance cut by $0.64

Johnson & Johnson announced completion of the $1 billion acquisition of Firefly and a strategic collaboration plus equity investment in Sail, cutting 2026 adjusted EPS by $0.64.Key Highlights:Original SEC Filing: JOHNSON & JOHNSON [ JNJ ] - 8-K - Jul. 29, 2026This is an AI-powered summary. It may c…

Johnson & Johnson announced completion of the $1 billion acquisition of Firefly and a strategic collaboration plus equity investment in Sail, cutting 2026 adjusted EPS by $0.64.

Key Highlights:

Completed acquisition of Firefly Bio for $1.0B cash; accounted as an asset acquisition with ~ $1B IPR&D charge in Q3 2026.
Entered strategic collaboration and equity investment in Sail Biomedicines, including an exclusive option to acquire Sail for $2.58B.
Combined transactions reduce 2026 adjusted operational EPS and adjusted EPS by ~$0.64 ($0.46 from Firefly, $0.18 from Sail).
Company now expects ~ $1.36 EPS dilution in 2027 ( ~$0.08 Firefly; ~$1.28 Sail), contingent on milestones and option exercise.
Updated full-year 2026 guidance: adjusted operational EPS midpoint lowered to $10.94; adjusted EPS midpoint lowered to $11.04; sales and currency guidance largely maintained.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.